ACI’s Paragraph IV Disputes Conference
Biosimilars Clinical Studies & Analytical Similarity Summit
Speaker “Legal & Regulatory Implications of ‘Similarity’ and ‘Interchangeability,”
Biosimilars Clinical Studies & Analytical Similarity Summit
Legal & Regulatory Implications of ‘Similarity’ and ‘Interchangeability
World Generic Medicines Congress
Speaker, Update from the U.S.: Regulatory Exclusivities, Biosimilars Progress and New Court Decisions,”
Fordham University School of Law IP Summit
Speaker “Latest Developments in Pharma/Life Sciences Patent Litigation,”
14th Annual Business of Biosimilars Conference
Speaker, “Understanding the Nuts and Bolts of Biosimilar Regulatory Requirements,”
Momentum’s International Congress on Paragraph IV Litigation
Speaker, “Litigation Management Strategy Discussion,”
Genetic Engineering & Biotechnology News
Biosimilars Now Just About Ready to Roll
Following the U.S. Supreme Court’s decision to leave intact the Patent Protection and Affordable Care Act, the development of biosimilars to treat a wide variety of diseases and health conditions is poised to surge. The Act contains important provisions that create a pathway for the FDA to approve “biosimilar” versions of previously approved biotechnology...
Biosimilars Now Just About Ready to Roll View Publication Corporate Counsel Magazine
Claim Construction Strategies for Trial and Appeal in Pharma Litigation
FDLI’s conference on IP Throughout the Drug Development Lifecycle